| 证券代码：300406 | 证券简称：九强生物 | 公告编号：2025-120 | | --- | --- | --- | | 债券代码：123150 | 债券简称：九强转债 | | 北京九强生物技术股份有限公司 关于公司持股 5%以上股东增持公司股份计划实施完毕的公告 持股 5%以上的股东中国医药投资有限公司保证向本公司提供的信息内容真 实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 公司于 2025 年 12 月 22 日收到持股 5%以上股东国药投资出具的《中国医药 投资有限公司关于北京九强生物技术股份有限公司股份增持计划实施完毕的函》。 截至本公告披露日，本次增持计划已实施完毕，国药投资以集中竞价交易的方式 共增持股份 2,926,000 股，占公司总股本的 0.499%，占剔除公司回购账户股份 后总股本的 0.502%，增持金额为 39,719,980.00 元人民币。本次增持前后股东 持股情况如下： | | | | 本次增持前持有的股份 | 占当时剔除 | | 本次增持后持有的股份 | 占当前剔除 | | - ...

| 证券代码：300406 | 证券简称：九强生物 | 公告编号：2025-119 | | --- | --- | --- | | 债券代码：123150 | 债券简称：九强转债 | | 1. 本发明涉及一种自润滑回转装置和配备有该自润滑回转装置的检测仪器， 自润滑回转装置，包括：内圈，其设置有开口朝向径向外侧的容纳槽；外圈，其 安装在所述内圈的外围，并设置有与所述容纳槽相对应的凸台，所述凸台位于所 述容纳槽内；以及多个滑动片，其安装在所述凸台上，并位于所述容纳槽内；其 中，所述外圈和所述内圈能够围绕共同的轴线相对彼此转动，并且所述外圈能够 带动所述多个滑动片一起相对于所述内圈转动。本发明其利用滑动片减小内圈和 外圈之间的转动摩擦力，不再需要依赖润滑油脂，减少了维护工作量，另外，本 发明结构简单，制造成本低，有利于设备的模块化设计。 2. 本发明涉及一种偶联物的制备方法。具体而言，本发明的 6- 磷酸葡萄 糖脱氢酶突变体相较于野生型 6- 磷酸葡萄糖脱氢酶包含选自以下的一个突变： D306C、D375C、G426C。使用本发明的 6- 磷酸葡萄糖脱氢酶突变体所制备的检 测试剂盒，其特异性强、灵敏度高、操作方便 ...

Policy Developments - The National Medical Insurance Administration has issued a three-year action plan to enhance the efficiency of medical insurance fund settlement, aiming to complete annual settlements by March 31 each year starting in 2028, with settlement funds accounting for about 3% of the annual medical insurance fund allocation [2] Medical Device Approvals - Jiukang Bio has received a medical device registration certificate for its fructosamine testing kit, which is expected to enhance its product line in the in vitro diagnostic sector [5] - Yihuilong has obtained registration for its anti-phosphatidylserine/prothrombin IgM and IgG antibody testing kits, which will expand its automated chemiluminescence product line [6] - Kangzheng Pharmaceutical's oral JAK1 inhibitor, Povorcitinib, has been included in the "Breakthrough Therapy" list for treating non-segmental vitiligo in adults [7] Capital Market Activities - Fosun Pharma plans to invest a total of 1.412 billion yuan in Green Valley Pharmaceutical, acquiring a 53% stake through its subsidiary [9] - Paig Bio-Medical has announced a further extension of the lock-up period for cornerstone investors until April 30, 2026, and is raising approximately 296 million HKD for various strategic initiatives [10][11] Industry Developments - Nanjing has established a medical health merger and acquisition equity investment fund with a total investment of 800 million yuan, focusing on equity investment and asset management [13] - Zhenghai Bio has signed a 12 million yuan technical development contract with the Chinese Academy of Agricultural Sciences for the research and development of recombinant type III collagen products [14] - MicroPort Robotics has established a new medical technology company with a registered capital of 15 million yuan, focusing on the development and manufacturing of service robots [15] Public Opinion Alerts - Tongrentang has responded to allegations of false labeling regarding its Antarctic krill oil product, initiating legal action against the involved parties to protect consumer rights [17]

Policy Developments - The National Healthcare Security Administration (NHSA) has issued a three-year action plan to enhance the efficiency of medical insurance fund settlement, aiming to complete annual settlements by March 31 each year starting in 2028, with settlement funds accounting for about 3% of the annual medical insurance fund allocation [2] - This plan represents a systemic reform of the medical insurance system, addressing issues such as slow reimbursements for insured individuals and funding for medical institutions in the short term, while promoting scientific and refined management of medical insurance funds in the medium term [2] Medical Device Registration - The Deputy Director of the National Medical Products Administration, Lei Ping, attended a regional meeting on medical device registration management and conducted field research in Guangdong and Yunnan, emphasizing the need to align with the health demands of the people and plan for high-quality development in the medical device sector [3] Company Announcements - Jiukang Bio has received a medical device registration certificate for its fructosamine testing kit, which is expected to enhance its competitiveness in the in vitro diagnostic market, although future sales remain uncertain [5] - Yihuilong has obtained registration for its anti-phosphatidylserine/prothrombin IgM and IgG antibody testing kits, which will expand its product line in the autoimmune disease testing sector, with sales dependent on market conditions [6] - Kangzheng Pharmaceutical announced that its oral JAK1 inhibitor, Povorcitinib, has been included in the "Breakthrough Therapy" list for treating non-segmental vitiligo in adults [7] Capital Market Activities - Fosun Pharma plans to invest a total of 1.412 billion yuan in Green Valley Pharmaceutical, acquiring a 53% stake through its subsidiary [9] - Paig Bio Pharma-B has announced a further extension of the lock-up period for cornerstone investors until April 30, 2026, and is raising approximately 296 million HKD for various strategic initiatives [10] Industry Developments - A new medical health equity investment fund has been established in Nanjing with a total investment of 800 million yuan, focusing on private equity investments and asset management [12] - Zhenghai Bio has signed a 12 million yuan technology development contract with the Chinese Academy of Agricultural Sciences for the research and development of recombinant type III collagen products [13] - Beijing Weisi Weixiang Medical Technology Co., Ltd. has been established with a registered capital of 15 million yuan, focusing on the development and manufacturing of service robots [14] - Tongrentang Health has taken action against a product falsely labeled as produced by its subsidiary, initiating legal proceedings to protect consumer rights [15]

Group 1 - Shareholder Zhang Yu of Kehua Holdings plans to reduce his stake by up to 3%, amounting to no more than 5.83 million shares within three months [1] - Shanghai Ailu has signed a strategic cooperation agreement with Southern Road Machinery to provide packaging products for the dry-mixed mortar industry [2] - Xingyuan Zhuomei appointed Gong Chunming as the new deputy general manager [3] Group 2 - Tongyi Zhong's shareholder has set a preliminary transfer price of 15.47 yuan per share for a total of 4.27 million shares [4] - Anada's shareholder did not implement the planned share reduction of up to 2% by the deadline [5] - Rongchang Bio plans to repurchase shares worth between 20 million to 40 million yuan at a price not exceeding 95 yuan per share [6] Group 3 - Hainan Airport reported an 8.16% year-on-year increase in passenger throughput for November, totaling 2.09 million passengers [7] - Lanjian Intelligent plans to apply for a bank credit line of up to 1.2 billion yuan for various financial operations [8] - Xinlei Co. received a total of 561.43 million yuan in land acquisition and compensation payments [9] Group 4 - Foster reported a surplus of 321 million yuan from four fundraising projects, which will be used to supplement working capital [10] - China Southern Airlines experienced a 10.42% year-on-year increase in passenger turnover for November [12] - China National Airlines reported a 10.1% year-on-year increase in passenger turnover for November [17] Group 5 - Sanyou Chemical plans to register and issue mid-term notes not exceeding 1.3 billion yuan [18] - Quanyuan Spring used 60 million yuan of idle funds to purchase structured deposits [19] - Su Keng Agricultural Development appointed Zou Yi as the new deputy general manager [20] Group 6 - Jingneng Real Estate received approval to register mid-term notes totaling up to 2 billion yuan [21] - Dechang Co. received approval from the CSRC for a targeted issuance of shares [23] - Jiufeng Bio obtained a medical device registration certificate for its fructosamine testing kit [24] Group 7 - Jinzi Ham's president Guo Bo resigned for personal reasons, while Zheng Hu was appointed as the new president [25] - China Eastern Airlines reported a 10.35% year-on-year increase in passenger turnover for November [26] - Fengfan Co.'s controlling shareholder is in the process of acquiring 17.32% of the company's shares [27] Group 8 - Zhenghai Bio signed a technical development contract with the Chinese Academy of Agricultural Sciences for a collagen product project worth 12 million yuan [28] - Xinhua Insurance reported a 16% year-on-year increase in cumulative original insurance premium income for the first 11 months [29] - Jingjia Microelectronics' subsidiary completed key stages of its AI SoC chip project [30] Group 9 - Shanghai Pharmaceuticals' hydrochloride sotalol tablets passed the consistency evaluation for generic drugs [31] - Heshun Technology's subsidiary's carbon fiber project has entered a stable operational phase [32] - Spring Airlines reported an 18.02% year-on-year increase in passenger turnover for November [33] Group 10 - Huaxin New Materials proposed a mid-term dividend plan of 1 yuan per 10 shares [34] - Keda Li plans to increase capital by 300 million yuan for its wholly-owned subsidiary [35] - Jinguang Electric won a bid for a high-voltage direct current transmission project worth 84.86 million yuan [36] Group 11 - XGIMI Technology's subsidiary received a development notification for a vehicle-mounted projection project from a well-known domestic automotive manufacturer [37]

Group 1 - The core point of the article is that Jiukang Bio has received a medical device registration certificate for its "fructosamine testing kit" from the Beijing Drug Administration [1] - Jiukang Bio's revenue composition for the year 2024 is projected to be 100% from the healthcare sector [1] Group 2 - As of the report, Jiukang Bio has a market capitalization of 7.7 billion yuan [2] - There are concerns regarding the financial practices of related parties associated with Jiangsu Wuzhong, which may impact investor confidence [2]

| 证券代码：300406 | 证券简称：九强生物 公告编号：2025-118 | | --- | --- | | 债券代码：123150 | 债券简称：九强转债 | 北京九强生物技术股份有限公司 北京九强生物技术股份有限公司 董事会 2025年12月15日 北京九强生物技术股份有限公司（以下简称"公司"）于近日收到北京 市药品监督管理局颁发的《医疗器械注册证》，具体情况如下： | 序号 | 产品名称 | 注册证编号 | 注册 类别 | 注册证有效期 | 预期用途 | | --- | --- | --- | --- | --- | --- | | 1 | 果糖胺测定试剂盒 （NBT 法） | 京 械 注 准 20252400983 | Ⅱ | 自批准之日起有效期 至 2030 年 12 月 08 日 | 本试剂盒用于体外定量 测定人血清中果糖胺 （FRUC）的含量。 | 上述产品为雅培仪器封闭通道配套专用试剂，丰富了公司在体外诊断生 化细分领域产品线的品种，有利于进一步提升公司的核心竞争力和市场拓展 能力，对公司未来的经营将产生积极影响。上述产品实际销售情况取决于未 来市场推广效果，公司目前尚无法预测其对公司 ...

点击免费限量礼盒 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 12月9日，九强生物晚间发布公告称，公司股东邹左军、刘希、孙小林与 中国医药投资有限公司（以下简称"国药投资"） 签署《股份转让协 议》，前者拟通过协议转让方式向国药投资合计转让2931.54万股股份，占九强生物总股的5%，交易总价款达4.01亿元，每股转让价格为 13.68元。 主营业务为生化诊断、血凝检测、血型检测和肿瘤病理检测的研发、生产和销售。2020年，在国药投资正式成为九强生物第一大股东后，九强 生物与国药投资联手收购迈新生物，布局肿瘤筛查诊断，扩充病理诊断试剂和仪器产品线，提升技术研发能力和营销网络布局。 在福布斯排行榜中，九强生物是全国中小企业中唯一一家连续9年上榜的中国潜力100强企业 。 | 版 权 ： 本 文 部 分 素 材 源 自 网 络 ， 版 权 归 原 作 者 所 有 ， 观 点 代 表 作 者 本 人 ， 不 代 表 本 号 立 场 | 转 载 ： 须 本 号 授 权 ， 请 联 系 主 编 | 责 编 ： 安 安 | 视 觉 ： 长 艳 柱 ...

（编辑 丛可心） 证券日报网讯 12月11日晚间，九强生物发布公告称，公司近日获国家知识产权局颁发的1项发明专利证 书，专利号ZL202510542311.9，名称为"应用于凝血分析仪的反应杯导向和自润滑机构"，授权日2025年 12月5日，专利权期限20年。 ...

（文章来源：北京商报） 北京商报讯12月11日，九强生物发布公告称，公司于近期收到国家知识产权局颁发的1项专利证书，专 利名称为应用于凝血分析仪的反应杯导向和自润滑机构，专利号为ZL202510542311.9。 根据公告，该发明涉及一种应用于凝血分析仪的反应杯导向和自润滑机构，包括基座、环形压紧块、夹 紧弹性体，能够提高反应杯的定位精度，并提高反应杯放入反应杯安装腔后光学通道的清洁程度，从而 保证了检测的准确性，并且不再需要频繁清理光学通道。 ...